Results 1 to 10 of about 134,452 (250)
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
Cells, 2022 Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone +5 more
doaj +1 more source
Frontiers in Oncology, 2022 AimsTo evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS).MethodsForty-six symptomatic MM patients were included ...
Yujun Wei +7 more
doaj +1 more source
Blood Cancer Journal, 2022 We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen +13 more
doaj +1 more source
Cancer Medicine, 2022 Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen +8 more
doaj +1 more source
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
Blood Cancer Journal, 2021 MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori +13 more
doaj +1 more source
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
Protein & Cell, 2018 Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang +13 more
doaj +1 more source
Selinexor: Targeting a novel pathway in multiple myeloma
eJHaem, 2023 Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo +9 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2023 Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD +9 more
doaj +1 more source
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Cells, 2022 Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein +2 more
doaj +1 more source
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Antibodies, 2017 2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho +6 more
doaj +1 more source